DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Trading Up 1.3 %

NASDAQ:DBVT opened at $0.69 on Friday. The stock has a 50-day moving average price of $0.77 and a 200 day moving average price of $0.86. The stock has a market capitalization of $133.31 million, a P/E ratio of -1.77 and a beta of 0.75. DBV Technologies has a 12-month low of $0.65 and a 12-month high of $2.37.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. The firm had revenue of $8.88 million for the quarter, compared to analysts’ expectations of $1.10 million. During the same quarter last year, the business posted ($0.23) earnings per share. On average, research analysts predict that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. bought a new position in shares of DBV Technologies during the third quarter valued at approximately $94,000. Optiver Holding B.V. boosted its holdings in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares during the period. Finally, Cowen AND Company LLC bought a new position in DBV Technologies in the 4th quarter valued at $49,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.